We have identified the JAK2 V617F mutation in 90 patients with MPD’S, as well as a significant percentage of this mutation in the hematological malignancies (AML, ALL, CML). The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.